The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases
Open accessAbstract
Cardiometabolic diseases encompass those affecting the heart and vasculature as well as other metabolic problems, such as insulin resistance, diabetes, and non-alcoholic fatty liver disease. These diseases tend to have common risk factors, one of which is impaired adiponectin action. This may be due to reduced bioavailability of the hormone or resistance to its effects on target tissues. A strong negative correlation between adiponectin levels and cardiometabolic diseases has been well-documented and research shown that adiponectin has cardioprotective, insulin sensitizing and direct beneficial metabolic effects. Thus, therapeutic approaches to enhance adiponectin action are widely considered to be desirable. The complexity of adiponectin structure and function has so far made progress in this area less than ideal. In this article we will review the effects and mechanism of action of adiponectin on cardiometabolic tissues, identify scenarios where enhancing adiponectin action would be of clinical value and finally discuss approaches via which this can be achieved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several short peptides and small molecules have been identified today to target AdipoRs and mimic some of ApN effects.”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [120]
In the citing paper
“These receptor agonists can induce similar downstream signaling cascades to ApN, such as AMPK, p38MAPK, and PPARα [120] (Table 1).”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–222 of 222
Sahebkar, A., Ponzo, V., & Bo, S. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160405111354 · Cited by 22
de Almeida-Pititto, B., Ribeiro‐Filho, F. F., Santos, I. S., Lotufo, P. A., Benseñor, I. M., & Ferreira, S. R. G. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316665490 · Cited by 22
St. John’s Wort Promotes Adipocyte Differentiation and Modulates NF-κB Activation in 3T3-L1 Cells
Hatano, T., Sameshima, Y., Kawabata, M., et al. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00989 · Cited by 21
Jo, M. G., Kim, M. W., Jo, M. H., Abid, N. B., & Kim, M. O. (2019) · International Journal of Obesity · doi:10.1038/s41366-019-0383-3 · Cited by 21
Qian, X., Wang, H., Yang, G., Gao, Z., Luo, Y., Dong, A., Zhang, F., Xu, M., Liu, S., Yang, X., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0401-9 · Cited by 20
Is coffee and green tea consumption related to serum levels of adiponectin and leptin?
Azadbakht, L., Izadi, V., & Larijani, B. A. (2018) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_37_14 · Cited by 19
AdipoRon: a possible drug for colorectal cancer prevention?
Malih, S., & Najafi, R. (2015) · Tumor Biology · doi:10.1007/s13277-015-3911-3 · Cited by 18
Barnette, D. A., Davis, M. A., Dang, N. L., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.043 · Cited by 16
Aouida, M., Kim, K.-C., Shaikh, A. R., Pardo, J. M., Eppinger, J., Yun, D., Bressan, R. A., & Narasimhan, M. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065454 · Cited by 15
Gómez‐Martín, J. M., Balsa, J. A., Aracil, E., Insenser, M. R., Priego, P., Escobar-Morreale, H. F., & Botella-Carretero, J. I. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.10.003 · Cited by 15
Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
Tripathy, D., Clement, S. C., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., Mudaliar, S. R. D., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1745 · Cited by 14
Dib, J., Thomas, A., Delahaut, P., Fichant, E., Schänzer, W., & Thevis, M. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.03.027 · Cited by 14
Espinoza, S. E., Wang, C.-P., Tripathy, D., Clement, S. C., Schwenke, D. C., Banerji, M. A., Bray, G. A., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., et al. (2016) · AGE · doi:10.1007/s11357-016-9946-6 · Cited by 14
Davis, M. A., Barnette, D. A., Flynn, N. R., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00006 · Cited by 14
Malih, S., Saidijam, M., Mansouri, K., Pourjafar, M., Tafakh, M. S., Talebzadeh, F., & Najafi, R. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2214-0 · Cited by 13
Vaccaro, O., Lucisano, G., Masulli, M., Bonora, E., Prato, S. D., Rivellese, A. A., Giorda, C. B., Mocarelli, P., Squatrito, S., Maggioni, A. P., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00361 · Cited by 13
Miele, M., Costantini, S., & Colonna, G. (2011) · PLoS ONE · doi:10.1371/annotation/69357261-7e31-40e0-96ff-13cdc783c768 · Cited by 13
Osmotin reduced amyloid beta (Aβ) burden by inhibiting SREBP2 expression in APP/PS1 mice
Shah, S., Yoon, G. H., Chung, S. S., Abid, N. B., Kim, T. H., Lee, H. Y., & Kim, M. O. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.12 · Cited by 12
Gokulakrishnan, K., Indulekha, K., Ganesan, S., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0100 · Cited by 11
Luo, M., Oza‐Frank, R. B., Narayan, K. M. V., Gokulakrishnan, K., & Mohan, V. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400319 · Cited by 9
AdipoRon may be benefit for atherosclerosis prevention.
Esfahani, M., Shabab, N., & Saidijam, M. (2017) · PubMed Central · doi:10.22038/ijbms.2017.8228 · Cited by 9
Boudreau, A., Fuller, S. E., Ribnicky, D., et al. (2018) · Biology · doi:10.3390/biology7020022 · Cited by 4
Flagged first, then by citations
Cited by
Sorted by citations
Abou-Samra, M., Selvais, C. M., Dubuisson, N., & Brichard, S. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072620 · Cited by 72
Yoon, G., Shah, S. A., Ali, T., & Kim, M. O. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0847-1 · Cited by 34
Metadata
- Authors
- Liu, Y., Vu, V., & Sweeney, G.
- Affiliations
- York University (CA)
- Corresponding author
- Liu, Ying
- Sweeney, Gary
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-11
- Volume
- 10
- Pages
- 842-842
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC6918867
- OpenAlex
- W2995030404
- Cited by
- 69
- References
- 222
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 12 · 2023: 14 · 2022: 8 · 2021: 15 · 2020: 7
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- adiponectin, cardiometabolic disease, insulin resistance, diabetes mellitus, non-alcoholic fatty liver disease, adiponectin resistance, cardioprotection, insulin sensitization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
